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clinical trial participants aged ≥60 years
with episodic or chronic migraine: pooled
results from 3 randomized, double-blind,
placebo-controlled phase 3 studies
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Verena Ramirez Campos3, Lynda J. Krasenbaum3, Dagny Holle-Lee4, David Kudrow5 and Christian Lampl6,7

Abstract
Background: Although migraine is less common in older people, preventive treatment of migraine in these
individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy.
Additionally, evidence for migraine treatment efficacy, safety, and tolerability is limited in this population. We
evaluated efficacy, safety, and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that
selectively targets calcitonin gene–related peptide (CGRP), in clinical trial participants aged ≥60 years with episodic
migraine (EM) or chronic migraine (CM).
Methods: This analysis included data from 3 randomized, double-blind, placebo-controlled phase 3 studies: the
HALO EM study, HALO CM study, and FOCUS study in participants with EM or CM and prior inadequate response to
2–4 migraine preventive medication classes. Participants in all studies were randomized 1:1:1 to receive 12 weeks of
subcutaneous treatment with quarterly fremanezumab (Months 1/2/3: EM/CM, 675 mg/placebo/placebo), monthly
fremanezumab (Months 1/2/3: EM, 225 mg/225 mg/225 mg; CM, 675 mg/225 mg/225 mg), or matched monthly
placebo.
Results: These pooled analyses included 246 participants aged ≥60 years. Reductions in monthly migraine days
from baseline over 12 weeks were significantly greater with fremanezumab (least-squares mean change from
baseline [standard error]: quarterly fremanezumab, − 4.3 [0.59]; monthly fremanezumab, − 4.6 [0.54]) versus placebo
(placebo, − 2.3 [0.57]; both P < 0.01 vs placebo). As early as Week 1, significant reductions from baseline in weekly
migraine days were observed with fremanezumab versus placebo (both P < 0.01). With fremanezumab treatment
versus placebo, a significantly higher proportion of participants achieved ≥50% reduction in monthly migraine days,
and significant improvements in disability and quality-of-life outcomes were observed (P < 0.05). Proportions of
participants experiencing serious adverse events and adverse events leading to discontinuation were low and
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similar in the fremanezumab and placebo groups. Efficacy and safety results were comparable to the overall pooled
population (N = 2843).
Conclusions: This pooled subgroup analysis demonstrates that fremanezumab treatment is efficacious and welltolerated over 12 weeks in participants aged ≥60 years with EM or CM. These data may help healthcare providers
with clinical decision making and preventive treatment selection for older patients with migraine.
Trial registration: ClinicalTrials.gov identifiers: HALO CM: NCT02621931; HALO EM: NCT02629861; FOCUS:
NCT03308968.
Keywords: Episodic migraine, Chronic migraine, Fremanezumab, CGRP, Older age

Background
Migraine is the second leading cause of years lived with
disability globally and is associated with a substantial
negative impact on health-related quality of life [1–4].
Although migraine is less common in older people, a
high prevalence of psychiatric disorders, such as depression, anxiety, and sleep disturbances, and the presence
of multiple comorbidities, such as cardiovascular (CV)
disorders and diabetes, may be associated with even further worsening in quality of life [5–9]. For example, individuals with migraine may have a more than 5 times
greater risk of developing major depressive disorder
compared with those without migraine [10–13], and that
increased risk of depression is also observed in older
people with migraine [8]. In addition, preventive treatment of migraine in older patients may be more challenging due to polypharmacy, especially with respect to
medications used for comorbidities, and concerns
around cognitive impairment, influenced by comorbidities, medications, and lifestyle [5, 7].
Treatment for patients with migraine includes both
acute and preventive medications. For years, preventive
treatment options have included anticonvulsants, antidepressants, antihypertensives (eg, β-blockers), flunarizine,
and onabotulinumtoxinA [14, 15]. However, these preventive treatments are not specific to migraine and are
often unsatisfactory due to lack of efficacy, intolerability,
and poor adherence [16–18]. Some of these may also
have contraindications, especially in older patients.
There are currently 4 monoclonal antibodies (mAbs)
targeting the calcitonin gene–related peptide (CGRP)
pathway that are approved by the US Food and Drug
Administration (FDA) for the preventive treatment of
migraine [19–22]. Fremanezumab, a fully humanized
mAb (IgG2Δa) that selectively targets CGRP, has proven
efficacy for the preventive treatment of migraine in
adults [23–25]. Three randomized, double-blind,
placebo-controlled, phase 3 trials have demonstrated
that fremanezumab is well tolerated and efficacious in
the preventive treatment of episodic migraine (EM) and
chronic migraine (CM), even in individuals with

difficult-to-treat migraine [23–25]. Long-term safety and
efficacy of fremanezumab treatment was also demonstrated for up to 12 months in parallel-group phase 3
studies in participants with EM or CM [26].
The analyses presented here aim to evaluate the efficacy, safety, and tolerability of fremanezumab in participants ≥60 years of age with EM or CM, which would
add to the presently limited body of evidence regarding
migraine treatment efficacy, safety, and tolerability in
this population [5]. Given the worldwide increase in life
expectancy, migraine in older age is likely to become an
increasing issue over the next 40 years, with management likely confounded by other health problems and
consequent association with polypharmacy. Therefore,
these analyses with a selected age cutoff of ≥60 years
were performed.

Methods
Study design

This was a pooled subgroup analysis including data from
3 international, multicenter, randomized, double-blind,
placebo-controlled, parallel-group, phase 3 trials in participants with CM and EM: HALO CM (ClinicalTrials.gov
Identifier: NCT02621931), which included participants
with CM; HALO EM (ClinicalTrials.gov Identifier:
NCT02629861), which included participants with EM;
and FOCUS (ClinicalTrials.gov Identifier: NCT03308968),
which included participants with CM or EM who had a
documented inadequate response or contraindication to 2
to 4 classes of prior migraine preventive medications.
Detailed methods and study designs for the HALO and
FOCUS studies have been previously reported [23–25]
and are briefly summarized here.
Participant population
HALO CM and HALO EM

Participants eligible for the HALO studies included
adults (18–70 years of age) with a history of migraine
per International Classification of Headache Disorders
(ICHD)-3 beta criteria for ≥12 months prior to screening
with onset at ≤50 years of age. In the HALO CM study,
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CM was defined as headache on ≥15 days per month,
with ≥8 days fulfilling ICHD-3 beta criteria for migraine,
probable migraine, or use of triptan or ergot medications, over a period of 3 months [25]. In the HALO EM
study, EM was defined as headache on 6 to 14 days per
month, with ≥4 days fulfilling ICHD-3 beta criteria for
migraine, probable migraine, or use of triptan or ergot
medications [23]. Participants were excluded in both trials for use of onabotulinumtoxinA in the 4 months before screening, use of opioids or barbiturates on ≥4 days
per month, use of interventions or devices for migraine
in the 2 months before screening, or previous failure
from ≥2 medication clusters after ≥3 months of treatment (antiepileptics, calcium channel blockers, antidepressants, beta blockers) [23, 25]. Up to 30% of
participants were permitted the use of 1 preventive migraine medication if the dose was stable from ≥2 months
before the pretreatment period to the end of the treatment period [23, 25].
FOCUS

Eligible participants for the FOCUS study included the
same adult population as the HALO studies but with 1
key difference: eligible participants also had documented
inadequate response or contraindication within the past
10 years to 2 to 4 of the following classes of prior migraine preventive medications: β-blockers, anticonvulsants, tricyclic antidepressants, calcium channel
blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, and valproic acid [24]. An inadequate response was defined as documentation in their medical
record of no clinically meaningful improvement (per the
treating physician’s judgment) after 3 months of stably
dosed treatment or discontinuation due to poor tolerability [24].
Standard protocol approvals, registrations, and
participant consents

All 3 studies were conducted in accordance with their
respective study protocols and the International Conference for Harmonisation guidelines for Good Clinical
Practice, the Declaration of Helsinki, and relevant national and local regulations. The study protocols were
approved by the appropriate ethics committees and institutional review boards. Participants provided written
informed consent prior to performing any study procedure or assessment [23–25].
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(Month 1/2/3: 675 mg/placebo/placebo), monthly fremanezumab (Month 1/2/3: CM, 675 mg/225 mg/225 mg;
EM, 225 mg/225 mg/225 mg), or matched monthly placebo. Efficacy was evaluated using information entered
by participants in a daily electronic headache diary
throughout the treatment period [23–25].

Outcome measures

Post hoc analyses were conducted using these pooled
data to assess the efficacy and safety of fremanezumab in
a subgroup of participants ≥60 years of age. Efficacy outcomes in the overall pooled population are also presented here for comparison.
Outcome measures assessed in participants ≥60 years included the following: mean change from baseline (28-day
pretreatment period) in the monthly average number of migraine days during the 12-week treatment period; monthly
average number of headache days of at least moderate severity during the 12-week treatment period; monthly average number of days of any acute headache medication use;
and weekly average number of migraine days during the
first 4 weeks of treatment.
For this subgroup of participants ≥60 years, the following outcomes were also assessed:
 Proportion of participants with ≥50% reduction







Study design

All 3 studies included a screening visit, a 28-day pretreatment period, a 12-week treatment period (doubleblind and placebo-controlled), and a final evaluation at
Week 12. Enrolled participants were randomly assigned
1:1:1 to receive subcutaneous quarterly fremanezumab



from baseline (28-day pretreatment period) in the
monthly average number of migraine days during
the 12-week treatment period
Mean change from baseline (Day 0) in scores on the
6-item Headache Impact Test (HIT-6; scores range
from 36 to 78, with higher scores indicating greater
impact of headache on functional status and wellbeing) [27] at 4 weeks after the last dose of study
drug
Mean change from baseline (Day 0) in scores on the
Migraine Disability Assessment (MIDAS; scores
range from 0 to 270, with higher scores indicating
more severe disability) [28, 29]
Mean change from baseline (Day 0) in domain
scores on the Migraine-Specific Quality of Life
(MSQoL) questionnaire (domains assessed: role
function-restrictive [RFR; 7 items on how migraine
limits daily activities], role function-preventive [RFP,
4 items on how migraine prevents these activities],
emotional function [EF; 3 items on the emotional effects of migraine] [30]; scores range from 0 to 100,
with higher scores indicating better health-related
quality of life) at 4 weeks after the last dose of study
drug
Proportion of participants classified as responders
on the Patient Global Impression of Change (PGIC;
responder defined as an individual who reported a
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rating of 5–7 [moderately better, better, or a great
deal better] on the PGIC)
 Change from baseline (Day 0) in domain scores on
the Work Productivity and Activity Impairment
(WPAI) assessment (percent work time missed due to
health, percent impairment while working due to
health, percent overall work impairment due to health,
percent activity impairment due to health) [31]
Adverse events (AEs), serious AEs (SAEs), AEs leading
to discontinuation, and CV AEs in participants with a
CV medical history were also assessed.
Statistical analyses

Efficacy analyses were conducted in the full analysis set,
which included all randomly assigned participants who
received ≥1 dose of study drug and had ≥10 days of postbaseline efficacy assessments on the primary endpoint.
Demographic and baseline characteristics were summarized descriptively. The mean change from baseline in
the monthly average number of migraine days, weekly
average number of migraine days, monthly average number of headache days of at least moderate severity,
monthly average number of days of acute medication
use, and MSQoL domain scores were analyzed using a
mixed-effects model for repeated measures (MMRM)
with treatment, sex or gender, study, region, month, and
treatment-by-month as fixed effects and baseline value
and years since onset of migraine as covariates. Mean
changes from baseline in the monthly average number
of migraine days and the monthly average number of
headache days of at least moderate severity were evaluated separately for people with CM and EM. Mean
changes from baseline in WPAI domain scores, HIT-6
scores, and MIDAS scores were evaluated using an analysis of covariance model with treatment, sex or gender,
study, and region as fixed effects and baseline score and
years since onset of migraine as covariates. The proportion of participants with a ≥ 50% reduction in the
monthly average number of migraine days was evaluated
using a logistic regression model with treatment, sex or
gender, and region as effects. Participants who discontinued early were considered non-responders for the overall
analysis and each month following discontinuation.
PGIC responder rates were evaluated using a CochranMantel-Haenszel (CMH) test stratified by study.
Adverse events, SAEs, AEs leading to discontinuation,
and CV AEs in participants with a CV medical history
were summarized descriptively.
Data availability

Anonymized data will be shared upon request from any
qualified investigator.
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Results
Participants

A total of 2843 participants were enrolled across all 3
studies (HALO CM, N = 1130; HALO EM, N = 875;
FOCUS, N = 838). The overall pooled full analysis population included 2823 participants (placebo, n = 939; quarterly fremanezumab, n = 939; monthly fremanezumab,
n = 945). Of these, 246 (8.7%) participants were ≥ 60
years of age and were included in these analyses (placebo, n = 80; quarterly fremanezumab, n = 74; monthly
fremanezumab, n = 92). Demographics and baseline
characteristics for participants ≥60 years were similar
across treatment groups. The mean age ranged from approximately 63 to 64 years, 81% to 84% of participants
were female, and the mean time since initial migraine
diagnosis was approximately 37 to 38 years (Table 1).
Chronic migraine (60%) was more common in this
pooled subpopulation aged ≥60 years than EM (40%). As
expected, time since initial migraine diagnosis was longer in the subgroup of participants aged ≥60 years than
in the overall pooled population due to this subpopulation’s advanced age. For participants with a CV medical
history at baseline, the most commonly reported types
of CV medical history were hypertension (50%–71%)
and varicose vein (0%–10%; Additional file 1).
Monthly migraine days, monthly headache days of at
least moderate severity, and days of acute medication
use

Among participants aged ≥60 years in the pooled analysis,
fremanezumab treatment resulted in significantly greater
reductions from baseline during 12 weeks of double-blind
treatment in the monthly average number of migraine
days compared with placebo (least-squares mean [LSM
(standard error [SE])] change from baseline: placebo,
− 2.3 [0.57]; quarterly fremanezumab, − 4.3 [0.59];
monthly fremanezumab, − 4.6 [0.54], both P < 0.01 vs placebo; Fig. 1A) Compared with placebo, reductions from
baseline during 12 weeks of double-blind treatment in
monthly average migraine days were also shown to be
significantly greater with both quarterly and monthly
fremanezumab in participants aged ≥60 years with EM
(P < 0.05 for both quarterly and monthly fremanezumab vs placebo) and with monthly fremanezumab in
participants aged ≥60 years with CM (P < 0.01 for
monthly fremanezumab vs placebo. Fig. 1B).
During the first 4 weeks of the double-blind treatment
period in participants aged ≥60 years, the reduction from
baseline in the weekly average number of migraine days
was significantly greater with fremanezumab compared
with placebo at each weekly time point from Week 1
(LSM [SE] change from baseline: placebo, − 0.4 [0.20];
quarterly fremanezumab, − 1.1 [0.21]; monthly fremanezumab, − 1.1 [0.19], both P < 0.01 vs placebo) through
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Table 1 Demographics and baseline characteristics of participants ≥60 years of age and overall population
Participants ≥60 years of age

Overall pooled population
Quarterly
fremanezumab
n = 943

Monthly
fremanezumab
n = 954

Placebo
n = 945

Quarterly
fremanezumab
n = 74

Monthly
fremanezumab
n = 92

Placebo
n = 80

Age, years, mean (SD)

42.8 (11.83)

43.0 (12.09)

42.9 (12.02)

63.5 (2.96)

63.2 (3.15)

64.0 (2.83)

Female, n (%)

811 (86)

813 (85)

808 (86)

60 (81)

77 (84)

67 (84)

White, n (%)

787 (83)

804 (84)

787 (83)

71 (96)

81 (88)

70 (88)

BMI, kg/m2, mean (SD)

26.3 (4.98)

26.0 (4.94)

26.4 (4.81)

25.5 (4.14)

25.7 (4.18)

26.0 (4.01)

Chronic migraine

545 (58)

553 (58)

541 (57)

56 (76)

46 (50)

45 (56)

Episodic migraine

398 (42)

401 (42)

404 (43)

18 (24)

46 (50)

35 (44)

21.1 (12.77)

21.5 (12.88)

21.2 (12.92)

37.3 (13.06)

38.0 (12.31)

37.1 (12.49)

Migraine classification, n (%)

Time since initial migraine
diagnosis, years, mean (SD)

SD, standard deviation; BMI, body mass index

Week 4 (placebo, − 0.5 [0.19]; quarterly fremanezumab,
− 1.2 [0.20], P < 0.05 vs placebo; monthly fremanezumab,
− 1.2 [0.18], P < 0.01 vs placebo; Fig. 2A).
In this pooled analysis, treatment with fremanezumab
resulted in a significantly greater reduction in the monthly

Fig. 1 Change in monthly migraine days during 12 weeks A) overall
and B) by migraine classification. Data shown are the LSM changes
from baseline in the monthly average number of migraine days
during 12 weeks of double-blind treatment. Part A includes data for
participants ≥60 years and the overall pooled population; part B
includes data for participants ≥60 years by migraine diagnosis
(chronic or episodic migraine). LSM, least-squares mean; LSMD, leastsquares mean difference; SE, standard error. aP < 0.01 vs placebo.
b
P < 0.005 vs placebo. cP < 0.0001 vs placebo. dP < 0.05 vs placebo

average number of headache days of at least moderate severity compared with placebo during 12 weeks of treatment in participants aged ≥60 years (LSM [SE] change
from baseline: placebo, − 2.1 [0.53]; quarterly fremanezumab, − 3.9 [0.55], P < 0.05 vs placebo; monthly fremanezumab, − 4.2 [0.51], P < 0.01 vs placebo; Fig. 3A). Reductions
in monthly average headache days of at least moderate severity from baseline during 12 weeks of double-blind
treatment were significantly greater with quarterly and
monthly fremanezumab compared with placebo in participants aged ≥60 years with EM (P < 0.05 for both quarterly
and monthly fremanezumab vs placebo) and with monthly
fremanezumab compared with placebo in the CM subset
(P < 0.01 for monthly fremanezumab vs placebo; Fig. 3B).
Among participants ≥60 years of age, the proportion of
participants with ≥50% reduction in the monthly average
number of migraine days during 12 weeks of treatment
was significantly greater with monthly fremanezumab
compared with placebo (placebo, 25%; quarterly fremanezumab, 36%, P = 0.12 vs placebo; monthly fremanezumab, 40%, P < 0.05 vs placebo; Fig. 4).
During 12 weeks of treatment, quarterly and monthly
fremanezumab treatment resulted in significantly greater
reductions from baseline in the monthly average number
of days of acute medication use compared with placebo
in participants aged ≥60 years (LSM [SE] change from
baseline: placebo, − 1.3 [0.55]; quarterly fremanezumab,
− 3.7 [0.56], P < 0.001 vs placebo; monthly fremanezumab, − 4.0 [0.52], P = 0.0001 vs placebo; Fig. 5).
These reductions in the monthly average number of
migraine days, weekly average number of migraine days,
monthly average number of headache days of at least
moderate severity, and monthly average number of days
of acute medication use for participants aged ≥60 years
were comparable to those for the overall pooled population (Figs. 1, 2B, 3, 4, and 5).
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Fig. 2 Change in weekly migraine days in A) participants aged ≥60
years and B) overall population. LSM, least-squares mean; LSMD,
least-squares mean differences; SE, standard error. Data shown are
the LSM changes from baseline in the weekly average number of
migraine days over the first 4 weeks of double-blind treatment.
a
P < 0.01 vs placebo. bP < 0.05 vs placebo. cP < 0.0001 vs placebo

Disability and quality-of-life outcomes

During the 12-week treatment period, reductions from
baseline in HIT-6 scores in participants aged ≥60 years
were greater with fremanezumab versus placebo, with
significant differences for monthly fremanezumab compared with placebo (LSM [SE] change from baseline: placebo, − 2.7 [0.92]; quarterly fremanezumab, − 4.3 [0.89],
P = 0.1585 vs placebo; monthly fremanezumab, − 6.8
[0.94], P = 0.0005 vs placebo; Fig. 6A). The LSM difference (SE) in the change in HIT-6 score for monthly fremanezumab versus placebo (− 4.2 [1.17]) met the 2.3point criterion for a clinically meaningful improvement
[32].
Reductions from baseline in MIDAS scores during 12
weeks of treatment in participants aged ≥60 years were also
greater with both fremanezumab dosing regimens compared
with placebo, with a significant difference for monthly fremanezumab compared with placebo (placebo, − 11.0 [3.85];
quarterly fremanezumab, − 21.7 [4.37], P = 0.0506 vs placebo;
monthly fremanezumab, − 24.0 [3.56], P < 0.01 vs placebo;
Fig. 6B).
MSQoL scores improved from baseline in participants
aged ≥60 years with both fremanezumab dosing regimens across all domains, including the RFR score and
EF scores (Fig. 7A). These improvements in MSQoL
scores at 3 months were significantly greater with both
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Fig. 3 Change in monthly headache days during 12 weeks A)
overall and B) by migraine classification. LSM, least-squares
mean; LSMD, least-squares mean difference; SE, standard error.
Data shown are the LSM changes from baseline in the monthly
average number of headache days of at least moderate severity
during 12 weeks of double-blind treatment. Part A includes data
for participants ≥60 years and the overall pooled population; part
B includes data for participants ≥60 years by migraine diagnosis
(chronic or episodic migraine). aP < 0.05 vs placebo. bP < 0.005 vs
placebo. cP < 0.0001 vs placebo

fremanezumab dosing regimens compared with placebo
for participants aged ≥60 years for the RFR and EF
scores (all P < 0.05 vs placebo).
Improvements in all WPAI domain scores were observed
in
participants
aged
≥60 years
with

Fig. 4 Participants achieving ≥50% response in participants aged
≥60 years and overall population. OR, odds ratio; CI, confidence
interval. A ≥ 50% response was defined as a ≥ 50% reduction from
baseline in the monthly average number of migraine days during
12 weeks of double-blind treatment. aP < 0.05 vs placebo. bP < 0.0001
vs placebo
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activity impairment score for monthly fremanezumab
(all P < 0.05 vs placebo).
The proportion of participants aged ≥60 years who were
classified as responders on the PGIC scale (score ≥ 5) was
significantly higher with both fremanezumab dosing regimens compared with placebo (both P < 0.01; Fig. 9).
Improvements in HIT-6, MIDAS, MSQoL, WPAI, and
PGIC scores for the subgroup of participants aged ≥60
years were comparable to those in the overall pooled
population (Figs. 6, 7B, 8B, and 9).
Fig. 5 Change in monthly days of acute medication use in
participants aged ≥60 years and overall population. LSM, leastsquares mean; LSMD, least-squares mean difference; SE, standard
error. Data shown are the LSM changes from baseline in the
monthly average number of days of acute headache medication use
during 12 weeks of double-blind treatment. aP < 0.001 vs placebo.
b
P ≤ 0.0001 vs placebo

fremanezumab treatment (Fig. 8A). Compared with placebo, improvements in WPAI scores were significantly
greater for the percent impairment while working domain score for both fremanezumab dosing regimens,
for the percent overall work impairment domain score
for quarterly fremanezumab, and for the percent

Fig. 6 Change in A) HIT-6 and B) MIDAS scores in participants aged
≥60 years and overall population. HIT-6, 6-item Headache Impact
Test; MIDAS, Migraine Disability Assessment; LSM, least-squares
mean; LSMD, least-squares mean difference; SE, standard error. Data
shown are the LSM changes from baseline in HIT-6 and MIDAS
scores during 12 weeks of double-blind treatment. aP = 0.0005 vs
placebo. bP < 0.0001 vs placebo. cP < 0.01 vs placebo

Safety

This pooled analysis of AEs reported in a subgroup of
participants aged ≥60 years showed that fremanezumab
was generally safe and well tolerated. In the overall subgroup of participants ≥60 years of age, AEs were reported for similar proportions of participants across
treatment groups. Serious AEs (all treatment groups,
3%) and AEs leading to discontinuation (quarterly fremanezumab, 1%; monthly fremanezumab, 1%; placebo,
3%) were infrequent in participants receiving fremanezumab and comparable to placebo. The most common
AEs were injection-site induration, injection-site pain,
and injection-site erythema (Table 2). Among participants aged ≥60 years with a CV medical history, CV AEs
occurred in a similar proportion of participants with or
without a CV medical history (Table 3). There was only
one SAE reported in participants aged ≥60 years with a
CV medical history, and none reported in participants
aged ≥60 years without a CV medical history. These
safety results are comparable to those in the overall
pooled population (any AE, quarterly fremanezumab
[65%], monthly fremanezumab [62%], placebo [58%];
SAEs, quarterly fremanezumab [<1%], monthly fremanezumab [1%], placebo [2%]; AEs leading to discontinuation,
quarterly
fremanezumab
[1%],
monthly
fremanezumab [2%], placebo [2%]; any CV AE with CV
medical history, quarterly fremanezumab [4%], monthly
fremanezumab [6%], placebo [4%]).

Discussion
As compared with placebo, fremanezumab treatment resulted in reductions of approximately 2 days from baseline in the monthly average number of migraine days
and in the monthly average number of headache days of
at least moderate severity over 12 weeks in this subgroup
of participants ≥60 years of age. Reductions in migraine
days were seen as early as Week 1 with fremanezumab
treatment, and consistent significant reductions were observed with both fremanezumab dosing regimens compared with placebo during each of the first 4 weeks of
treatment. The proportion of participants achieving clinically meaningful response rates (≥50% reduction in
monthly average number of migraine days) with
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Fig. 7 Change in MSQoL domain scores in A) participants aged ≥60 years and B) overall population. MSQoL, Migraine-specific Quality of Life;
RFR, role-function restrictive; RFP, role-function preventive; EF, emotional function; LSM, least-squares mean; LSMD, least-squares mean difference;
SE, standard error. Data shown are the LSM changes from baseline in MSQoL domain scores at Week 12. aP < 0.05 vs placebo. bP < 0.0005 vs
placebo. cP < 0.01 vs placebo. dP < 0.0001 vs placebo

fremanezumab was 11% higher with quarterly dosing
and 15% higher with monthly dosing compared with placebo; the difference between fremanezumab and placebo
was statistically significant for monthly fremanezumab,
but not quarterly fremanezumab. Additionally, over 12
weeks of fremanezumab treatment, participants aged
≥60 years experienced an approximately 2.5-day per
month greater reduction in days of acute headache
medication use than with placebo. These results were
comparable to those observed in the overall pooled
population.
In participants aged ≥60 years, treatment with quarterly or monthly fremanezumab over 12 weeks resulted
in clinically meaningful improvements in a variety of
outcomes related to quality of life. Participants receiving

fremanezumab experienced significantly greater improvements in headache-related disability, based on reductions in MIDAS and HIT-6 scores, as compared with
participants who received placebo. Improvements from
baseline versus placebo were observed with fremanezumab in all MSQoL and WPAI domains. The proportion
of participants categorized as PGIC responders was also
significantly greater with fremanezumab versus placebo.
Although migraine treatment may be more difficult in
older patients [5, 7], fremanezumab showed comparable,
or for some endpoints numerically better, efficacy in the
subgroup of participants aged ≥60 years and in the overall pooled population. For example, for the WPAI domain of work time missed, fremanezumab showed
numerically greater improvements from baseline in the
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Fig. 8 Change in WPAI domain scores in A) participants aged ≥60 years and B) overall population. WPAI, Work Productivity and Activity
Impairment; LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. Data shown are the LSM changes from baseline in
WPAI domain scores during 12 weeks of double-blind treatment. aP < 0.005 vs placebo. bP < 0.05 vs placebo. cP < 0.01 vs placebo. dP ≤ 0.001 vs
placebo. eP < 0.0001 vs placebo. fP < 0.0005 vs placebo

Fig. 9 Proportion of PGIC responders in participants aged ≥60 years
and the overall population. PGIC, patient global impression of
change. Data shown are the proportion of PGIC responders (defined
as individuals who reported a rating of 5–7 [moderately better,
better, or a great deal better] on the PGIC) at Week 12. aP < 0.01 vs
placebo. bP < 0.005 vs placebo. cP < 0.0001 vs placebo

subgroup aged ≥60 years compared with the overall
population. This consistency of the efficacy of fremanezumab in this subgroup of participants aged ≥60 years
with that in the overall pooled population provides evidence that fremanezumab is effective in reducing migraine in older individuals, including those with difficultto-treat migraine.
Determining an optimal migraine preventive pharmacotherapy plan for older patients can be challenging due
to the traditionally lower participation rates by older
people with migraine, as well as restrictive exclusion criteria in most migraine clinical trials [5]. The safety profile for fremanezumab in participants aged ≥60 years is
consistent across treatment groups and is comparable to
the overall pooled population. Generally, AEs were infrequent in older participants with a CV medical history.
Of note, considering the higher risk for CV disease and
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Table 2 Overall AEs in participants ≥60 years of age with ≥5% incidence in any treatment group
AEs, n (%)

Quarterly fremanezumab
(n = 74)

Monthly fremanezumab
(n = 92)

Placebo
(n = 80)

Any AE

48 (65)

53 (58)

44 (55)

SAEs

2 (3)

3 (3)

2 (3)

AEs leading to discontinuation

1 (1)

1 (1)

2 (3)

23 (25)

14 (18)

Most common AEs (incidence ≥5% in any treatment group)
Injection-site induration

11 (15)

Injection-site pain

13 (18)

19 (21)

10 (13)

Injection-site erythema

8 (11)

10 (11)

13 (16)

Nasopharyngitis

4 (5)

5 (5)

4 (5)

AE, adverse event; SAE, serious adverse event

other comorbidities among older individuals [9, 33],
rates of CV AEs were low, even in participants with a
CV medical history. Further, there were no SAEs reported in this subgroup.
Whereas migraine is more common in individuals
younger than 55 years, a considerable proportion of
people older than this also experience migraine [7, 9,
33]. Many cross-sectional studies have shown that migraine persists in people aged ≥60 years, with a prevalence of approximately 5% even in those older than
75 years [34]. Currently, there are no subgroup analyses for other mAbs targeting the CGRP ligand that
examined efficacy in older study participants with migraine. Erenumab is the only other CGRP pathwaytargeted mAb (receptor targeted) that has analyzed
safety and tolerability in subgroups of older study
participants (50–55 and >55 years of age) with migraine. As with fremanezumab, treatment-emergent
AE rates were comparable for the erenumab treatment groups and the placebo group in these older
subgroups [35]. Rates of SAEs and AEs leading to discontinuation were also infrequent and similar across

the erenumab and placebo groups for these older participants [35].
The results of this subgroup analysis may be subject to
limitations. Although this analysis included participants
from 3 large studies, there were relatively small numbers
of participants ≥60 years in each group. The lower number of participants may have limited the ability to detect
significant between-group differences for all endpoints
(eg, the ≥50% response rate for change in monthly migraine days for quarterly fremanezumab versus placebo).
However, the results reported here may be generalizable
because the efficacy and safety results from the subgroup
were comparable to the overall pooled population. Additionally, of 7171 participants screened in the HALO and
FOCUS studies, 610 met the exclusion criteria, which included a history of clinically significant CV disease as
determined by the investigator, so the participants included in these analyses likely have a milder CV medical
history than older people with migraine in the general
population.
As mentioned, older individuals with migraine likely
have a range of comorbidities, including hypertension,

Table 3 Cardiovascular adverse events in participants ≥60 years of age with a cardiovascular medical history
CV AEs, n (%)
Participants with CV medical history
≥1 CV AE

Quarterly fremanezumab

Monthly fremanezumab

Placebo

(CM/EM: 675 mg/PBO/PBO)

(EM: 225/225/225 mg)

(CM: 675/225/225 mg)

(n = 30)

(n = 6)

(n = 14)

(n = 23)

1 (3)

0

2 (14)

1 (4)

AEs with incidence ≥1 participant in any treatment/dose group
Palpitations

0

0

1 (7)

1 (4)

Hypertensive crisis

0

0

1 (7)

0

Supraventricular tachycardia

1 (3)

0

0

0

(n = 44)

(n = 40)

(n = 32)

(n = 57)

0

0

2 (6)

0

Participants without CV medical history
≥1 CV AE

AEs with incidence ≥1 participant in any treatment/dose group
Hot flush

0

0

1 (3)

0

Hypertension

0

0

1 (3)

0

CM, chronic migraine; EM, episodic migraine; PBO, placebo; CV, cardiovascular; AE, adverse event
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heart disease, or psychiatric disorders, that also influence
management of their migraine [7, 33]. Even in a complex
population, effective migraine management may improve
their quality of life [7, 33]. With a favorable safety profile, these results demonstrate that fremanezumab may
be an effective migraine preventive treatment option for
older individuals with difficult-to-treat disease.

Conclusions
This pooled subgroup analysis demonstrated that fremanezumab treatment was effective in reducing migraine
days, headache days of at least moderate severity, and days
of acute medication use over 12 weeks of treatment in participants aged ≥60 years with EM or CM. Additionally, fremanezumab improved quality of life and headache-related
disability in this older population. The consistent efficacy
and safety results of fremanezumab across treatment
groups in this subgroup analysis demonstrate that fremanezumab is an effective preventive treatment option for
individuals ≥60 years of age, including those with comorbidities and difficult-to-treat EM or CM.
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